TY - JOUR
T1 - Patient-derived xenograft models for endometrial cancer research
AU - Moiola, Cristian P.
AU - Lopez-Gil, Carlos
AU - Cabrera, Silvia
AU - Garcia, Angel
AU - van Nyen, Tom
AU - Annibali, Daniela
AU - Fonnes, Tina
AU - Vidal, August
AU - Villanueva, Alberto
AU - Matias-Guiu, Xavier
AU - Krakstad, Camilla
AU - Amant, Frédéric
AU - Gil-Moreno, Antonio
AU - Colas, Eva
PY - 2018
Y1 - 2018
N2 - Endometrial cancer (EC) is the most common malignancy of the genital tract among women in developed countries. Recently, a molecular classification of EC has been performed providing a system that, in conjunction with histological observations, reliably improves EC classification and enhances patient management. Patient-derived xenograft models (PDX) represent nowadays a promising tool for translational research, since they closely resemble patient tumour features and retain molecular and histological features. In EC, PDX models have already been used, mainly as an individualized approach to evaluate the efficacy of novel therapies and to identify treatment-response biomarkers; however, their uses in more global or holistic approaches are still missing. As a collaborative effort within the ENITEC network, here we describe one of the most extensive EC PDX cohorts developed from primary tumour and metastasis covering all EC subtypes. Our models are histologically and molecularly characterized and represent an excellent reservoir of EC tumour samples for translational research. This review compiles the information on current methods of EC PDX generation and their utility and provides new perspectives for the exploitation of these valuable tools in order to increase the success ratio for translating results to clinical practice.
AB - Endometrial cancer (EC) is the most common malignancy of the genital tract among women in developed countries. Recently, a molecular classification of EC has been performed providing a system that, in conjunction with histological observations, reliably improves EC classification and enhances patient management. Patient-derived xenograft models (PDX) represent nowadays a promising tool for translational research, since they closely resemble patient tumour features and retain molecular and histological features. In EC, PDX models have already been used, mainly as an individualized approach to evaluate the efficacy of novel therapies and to identify treatment-response biomarkers; however, their uses in more global or holistic approaches are still missing. As a collaborative effort within the ENITEC network, here we describe one of the most extensive EC PDX cohorts developed from primary tumour and metastasis covering all EC subtypes. Our models are histologically and molecularly characterized and represent an excellent reservoir of EC tumour samples for translational research. This review compiles the information on current methods of EC PDX generation and their utility and provides new perspectives for the exploitation of these valuable tools in order to increase the success ratio for translating results to clinical practice.
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85052156073&origin=inward
UR - https://www.ncbi.nlm.nih.gov/pubmed/30126113
U2 - https://doi.org/10.3390/ijms19082431
DO - https://doi.org/10.3390/ijms19082431
M3 - Review article
C2 - 30126113
SN - 1661-6596
VL - 19
JO - International journal of molecular sciences
JF - International journal of molecular sciences
IS - 8
M1 - 2431
ER -